Metastatic adenocarcinoma of the esophagus to the skin: New patterns of tumor recurrence and alternate treatments for palliation

Journal of Cutaneous Pathology

Volumn 28, Issue 8, 2001, Pages 425-431

  Smith, Kathleen J ^a   Williams, John ^a   Skelton, Henry ^b,c  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ACTIN; CD34 ANTIGEN; MONOCLONAL ANTIBODY; PROTEIN BCL 2; PROTEIN P53; PROTEIN S 100;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; ESOPHAGUS CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PALLIATIVE THERAPY; PROTEIN EXPRESSION; SKIN METASTASIS; STAINING; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADENOCARCINOMA; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PALLIATIVE CARE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034877769     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2001.028008425.x     Document Type: Article

References (41)

1. Endoscopic diagnosis and treatment of esophageal cancer
2. Advances in the treatment of esophageal carcinoma
3. Barrett's esophagus
4. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
5. Helicobacter pylori infection: Independent risk indicator of gastric adenocarcinoma
6. Rising incidence rate of esophageal adenocarcinoma and use of pharmaceutical agents that relax the lower esophageal sphincter
7. Cytokeratins in the histological diagnosis of malignant tumors
8. Cytokeratin subsets can reliably distinguish Barrett's esophagus from intestinal metaplasia of the stomach
9. Overexpression of p53 protein associates decreased response to chemoradiotherapy in patients with esophageal carcinoma
10. p53 protein accumulation and p53 gene mutation in esophageal carcinoma: A molecular and immunohistochemical study with clinicopathologic correlations
11. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
12. p53 status and the efficacy of cancer therapy in vivo
13. Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells
14. Expression of wild-type p53 gene confers increased sensitivity to radiation and chemotherapeutic agents in human esophageal carcinoma cells
15. Amplification and overexpression of the EGFR and erbB2 genes in human esophageal adenocarcinomas
16. The biology of erbB-2/neu/HER-2 and its role in cancer
17. Anticancer drug targets: Growth factors and growth factor signaling
18. ErbB-2 anti-sense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification
19. Expression of c-erB2 oncogene product in different tumours and its standardized evaluation
20. Cyclooxygenase independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma
21. Chemopreventive efficacy of sulindac sulfaone against colon cancer depends on time administration during carcinogenic process
22. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
23. Role of arachidonic acid metabolites in tumor growth inhibition by nonsteroidal anti-inflammatory drugs
24. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition
25. Synergistic effects of 13-cis retinoic acid and arachidonic acid cascade inhibitors on growth of head and neck squamous cell carcinoma in vitro
26. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
27. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal anti-inflammatory drugs
28. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
29. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
30. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumor growth in rabbits
31. p53: Radiosensitivity and antiangiogenic effects
32. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
33. Up-regulation of inducidble nitric oxide synthase expression in cancer-prone p53 knockout mice
34. Regulation of cycloxygenase 2 pathway by HER2 receptor
35. Resistence to apoptosis and cyclooxygenase-2 expression in human adenocarcinoma cell line HT29CL.19A
36. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines
37. Apoptosis primarily accounts for the growth inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
38. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs
39. In vivo effects of prostaglandin E2 or indomethacin on the proliferation of lymphokine activated killer cells and their cytotoxicity against bladder tumor cells in patients with bladder cancer
40. Regulation of cycloxygenase 2 by interferon gamma and transforming growth factor alpha in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen activated protein kinases
41. Nonsteroidal anti-inflammatory drug metabolism potentiates interferon alfa signaling by increasing STAT 1 phosphorylation